Treatment and Monitoring of Eosinophilic Fasciitis
Selva O'Callaghan, Albert (Hospital Universitari Vall d'Hebron)
Trallero-Araguás, Ernesto (Hospital Universitari Vall d'Hebron)
Gil-Vila, Albert (Hospital Universitari Vall d'Hebron)
Guillén-Del-Castillo, Alfredo (Hospital Universitari Vall d'Hebron)
Matas-Garcia, Ana (Hospital Clínic i Provincial de Barcelona)
Milisenda, José César (Hospital Clínic i Provincial de Barcelona)
Simeón-Aznar, Carmen Pilar (Hospital Universitari Vall d'Hebron)
Pinal-Fernandez, Iago (Johns Hopkins University School of Medicine)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	Purpose of Review Eosinophilic fasciitis (EF) is a rare infammatory disease characterized by skin induration. Although some guidelines from scientifc societies exist, standard recommendations on monitoring and therapy are lacking. Recent Findings Current therapy for patients diagnosed with EF includes glucocorticoids plus at least one immunosuppressive drug in cases of relapse or refractory disease. Methotrexate and mycophenolate mofetil are the most recommended, although recently a myriad of case reports or small series reporting the efectivity of biological agents or JAK inhibitors for treating relapses or refractory disease have been published. Anti-IL5 may have a role in those rare refractory cases with persistent eosinophilia. Intravenous immunoglobulins and photopheresis (in those centers with experience) may act as adjuvant therapies. Monitoring the disease activity is a cornerstone to ascertain if the treatment is useful or not. MRI, PET/TC, and more specifcally POCUS have recently demonstrated their value for assessing therapy response. Summary High-quality data focused on therapy and monitoring is lacking in EF. Strategies for improving scientifc quality of observational studies and consensus about "activity", "sequela", "relapse" or "refractoriness" terms in EF patients are necessary to implement prospective clinical trials and generate evidence-based medicine. Meanwhile we have to deal with the available information.
Grants:	Instituto de Salud Carlos III PI22/00708
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Eosinophilic fasciitis ; Immunosuppressive treatment ; Monitoring ; Unmet needs ; Groove sign
Published in:	Current treatment options in rheumatology, Vol. 11 (January 2025) , ISSN 2198-6002

DOI: 10.1007/s40674-024-00222-6
PMID: 40115529

11 p, 1022.1 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles